Sermorelin side effects

Injection-site irritation and antibodies

In a study of 60 growth-hormone-deficient children, treatment with GHRH(1-29)-NH2 over 6 months produced no serious side effects; three children reported mild injection-site irritation. Nearly all developed antibodies to GHRH. No GH antibodies were detected, and the GHRH antibodies almost disappeared by 9 months after treatment stopped; they did not correlate with growth.

Antibodies are proteins made by the immune system in response to a substance. Their presence can be distinct from blocking its action. In a 12-to-24-month pediatric study, some responders developed GHRH antibodies without apparent interference with growth, and no glucose or lipid changes were noted.

I need that immune finding kept separate from a loss of treatment response. The animal work adds a narrower observation: in African green monkeys given natural GRF or a potent analogue, low-titer antibodies in one of six animals per group failed to impair stimulated GH secretion. That monkey result cannot settle human safety.

Glucose tolerance and lipid changes

The 14-day native GHRH(1-29) study in older men found unchanged fasting glucose. In the [16-week [Nle27] analogue study in older women and men](https://pubmed.ncbi.nlm.nih.gov/9141536/), fasting glucose and insulin, blood pressure and body weight were unchanged; a temporary rise in blood fats resolved by the end.

There is a less comfortable result from a different long-acting preparation. PEG-conjugated GHRH produced mild, transient injection-site reactions more often than placebo, and some impaired glucose tolerance in elderly subjects receiving repeated doses. No GHRH antibodies were observed.

These results concern different drugs and different windows of observation. I accept the reassurance each provides for its own measurements. A blanket claim of metabolic safety asks much more of them.

Other pituitary hormones

An acute intravenous study in short prepubertal children found small, short-term rises in prolactin, luteinizing hormone and follicle-stimulating hormone alongside GH. Those hormones have roles in milk production and reproductive function. The brief changes were not established as lasting health problems.

“Selective” action can be a useful pharmacological description while leaving these observations worth reporting. I want persistence and symptoms documented for an off-target change; this study leaves that larger clinical question open.

A fading response during continuous infusion

In children receiving continuous subcutaneous GHRH(1-29), an early GH increase gave way to a decline, with complete suppression in one child. Possible explanations included antibodies, somatostatin changes and pituitary receptor desensitization.

The research account follows that experiment in more detail. It is a caution about assuming that sustained stimulation will continue to produce the same response. It supplies no personal dosing advice.

Is sermorelin safe over years?

Growth hormone and IGF-1 support cell growth. Chronically raising them carries a theoretical cancer-related concern, discussed within the secretagogue rationale and the broader GHRH literature. Long-term human data have not resolved that concern. These sources do not establish that sermorelin caused cancer in the people studied.

My hope for adult trials is that they follow harms alongside everyday function and strength. Short observation periods leave those later outcomes unsettled, even where the initial hormone response looks tidy. The aging editorial’s caution rests on that incomplete case for sustained health benefit and safety.

Supply quality; sport restrictions

The critical review of peptide use in sport describes mislabeling and contamination outside a regulated pharmacy supply chain. The reviews of unapproved peptide therapies and injectable peptides in sports medicine add concerns about scarce human safety data. Product identity creates a further uncertainty beyond the molecule’s pharmacology.

WADA prohibits growth hormone secretagogues, including GHRH analogues. The review of detection methods and plasma identification study describe analytical work used to identify these substances. The sporting restriction is a separate issue from judging medical suitability.

Headache, puffiness, nausea and other community complaints are described separately as anecdotes. Personal medical assessment requires a clinician who can consider the individual’s illnesses, symptoms and other medicines.